Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines

European Journal of Medicinal Chemistry(2020)10.1016/j.ejmech.2020.112397Source: DataRank Database

Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines is a research paper published in European Journal of Medicinal Chemistry (2020). On theSindex it has a DataRank of 0. It has been cited 65 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access65 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 2.84)OA: greenTopics (48)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Yonghan He ORCID,Peiyi Zhang ORCID,Vivekananda Budamagunta,Dongwen Lv ORCID,Dinesh Thummuri ORCID

Live enrichment

PubMed:32388279 PMC:PMC7325632 OpenAlex:https://openalex.org/W3023706389

National Institutes of Health

Grant: R01CA219836

National Institutes of Health

Grant: R01CA242003

National Institutes of Health

Grant: R21CA223371

FWCI

2.84

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7325632

publisherhttps://api.elsevier.com/content/article/PII:S0223523420303676?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0223523420303676?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ejmech.2020.112397

Fields of Study

Protein Degradation and InhibitorsMultiple Myeloma Research and TreatmentsPeptidase Inhibition and AnalysisAntineoplastic AgentsCell ProliferationCell SurvivalCells, CulturedDose-Response Relationship, DrugDrug DiscoveryDrug Screening Assays, AntitumorHumansInhibitor of Apoptosis ProteinsMolecular StructureProteolysisStructure-Activity RelationshipUbiquitin-Protein Ligasesbcl-X Protein

MeSH Terms

Antineoplastic AgentsCell SurvivalCells, CulturedDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansStructure-Activity RelationshipMolecular StructureUbiquitin-Protein LigasesCell Proliferationbcl-X ProteinInhibitor of Apoptosis ProteinsDrug DiscoveryProteolysis

Keywords

Ubiquitin ligaseChemistryUbiquitinCell cultureDNA ligaseCereblonCancer researchBiologyBiochemistryGeneticsDNAGeneDegradationIAPsBcl-x(l)ProtacSniper

Sustainable Development Goals

SDG 0: Good health and well-being